Cigna Group Q2 Earnings Call Highlights

Cigna raised its full-year 2026 adjusted earnings outlook to at least $30.45 after reporting second-quarter results that management said exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment.

The company reported second-quarter total revenue of $71.7 billion, adjusted after-tax earnings of $2.1 billion and adjusted earnings per share of $7.78. Cigna also recorded after-tax special-item charges of $153 million, or $0.58 per share, during the quarter.

For the full year, Cigna increased its adjusted earnings-per-share outlook to at least $30.45. CFO Ann Dennison said the guidance reflects strong first-half performance while retaining what she described as a “prudent view” of the operating environment.

Evernorth Health Services generated $61.5 billion in second-quarter revenue, up 6% from a year earlier, and $1.7 billion in pretax adjusted earnings. Its Specialty and Care Services unit produced $1.1 billion in pretax adjusted earnings, a 22% year-over-year increase that exceeded management’s expectations.

Dennison attributed the performance to continued specialty-drug utilization growth, quicker-than-anticipated adoption of biosimilars and specialty generics, operating efficiencies and income from Cigna’s investment in Shields Health Solutions. She said specialty-generic penetration for newer products exceeded 80% in the quarter.

The company said increased biosimilar and specialty-generic adoption improves affordability for clients and patients, but it also shifts earnings within Evernorth. Dennison said the dynamic boosts Specialty and Care Services while reducing contributions from Pharmacy Benefit Services, in part because lower drug costs affect revenue and the economics of the pharmacy-benefits business.

Pharmacy Benefit Services reported pretax adjusted earnings of $609 million, down from the prior year and broadly in line with expectations. Management cited the impact of previously discussed extensions and renewals of large client contracts, as well as investment spending tied to the transition to its rebate-free pharmacy-benefits model, Signature.

Cigna said it expects full-year Evernorth pretax adjusted earnings of at least $6.9 billion. While specialty generics and biosimilars should remain a meaningful tailwind, Dennison said the magnitude of the second-quarter benefit is not expected to recur at the same level in the third and fourth quarters. Management also cited moderating GLP-1 prescription growth. Coverage levels declined slightly and utilization growth slowed from the elevated levels in earlier periods, a trend the company expects to continue through the rest of 2026.